Abstract

The ability of tumors to develop resistance to cytotoxic therapies has been a major obstacle in the clinical management of cancer. In addition, dose-limiting toxicity represents yet another impediment in the application of traditional therapeutics. To enhance the sensitivity of tumors to radio-therapeutics, researchers are increasingly turning to nitric oxide for its potential as a powerful adjuvant to existing therapies. Here, we review the aptitude of nitric oxide to serve as a radio-sensitizing, adjuvant therapeutic for the clinical management of cancer.